AbbVie forges $3.9 billion oncology alliance with Genmab

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgk

J&J defends Darzalex with FDA approval for faster dosing

Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPO

Denmark's Genmab prepares for $500m US IPO

Antibody-based drugs firm Genmab, noted for developing the blood cancer drug Darzalex with Johnson & Johnson’s Janssen unit, is preparing for a $500 million US IPO.

‘Trojan horse’ cancer drug shows promise in multiple tumour ...

A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.

J&J rumoured to be sizing up $12bn Genmab acquisition

Speculation mounts that J&J will bid for R&D partner